Ye Eun Kwak1, Stacy M Stein2, Joseph K Lim3. 1. Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, 267 Grant St, Bridgeport, CT, 06614, USA. 2. Department of Internal Medicine, Section of Medical Oncology and Smilow Cancer Center, Yale University School of Medicine, 35 Park St, Ste North Pavillion 8, New Haven, CT, 06511, USA. 3. Department of Internal Medicine, Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT, 06520-8019, USA. joseph.lim@yale.edu.
Abstract
BACKGROUND: Cancer patients receiving chemotherapy face an increased risk of reactivation of chronic hepatitis B virus infection. AIM: To determine the HBV screening rate in patients receiving cancer chemotherapy in various clinical settings. METHOD: We identified 11,959 adult cancer patients (age ≥ 18 years) receiving parenteral chemotherapy between 2012 and 2015 within a major US hospital network, including a large university hospital, community teaching hospitals, and community oncology clinics. RESULT: Two thousand and forty-five patients (17.1%) were screened for either HBV surface antigen (HBsAg) or HBV core antibody (HBcAb) before chemotherapy, and 1850 patients (15.5%) had both HBsAg and HBcAb tested before chemotherapy. 8.4% were exposed to HBV, and 0.9% had chronic HBV infection (both HBsAg/HBcAb positive). Patients with hematologic tumor were more often screened than with solid tumor (55.6 vs. 8.3%, p < 0.001). Patients receiving chemotherapy with higher HBV reactivation risk had higher yet suboptimal HBV screening rate (41.1% B-depleting agents, 21.5% anthracycline, 14.9% steroid, 64.7% anti-TNF alpha and 18.6% other chemotherapy, p < 0.001). Patients with age ≥ 50 years (old 16.2% vs. young 23.9%, p < 0.001) and Asian ethnicity (Asian 13.6 vs. Caucasian 16.6%, p < 0.001) were screened less for HBV despite higher prevalence of HBV exposure (old 9.3% vs. young 4.3%, p < 0.001 and Asian 27.8% vs. Caucasian 6.4%, p < 0.001). Patients receiving chemotherapy in community oncology clinics were less screened versus community teaching hospitals or university hospital (12.7 vs. 19.1 vs. 19.7%, p < 0.001), despite similar prevalence of HBV infection. On multivariate analysis, receiving chemotherapy at a community oncology clinic [odds ratio (OR) 0.57, 95% confidence interval (CI) 0.45-0.72, p < 0.001] was independently associated with less HBV screening compared to receiving chemotherapy at a university or community teaching hospital. CONCLUSION: HBV screening among patients undergoing cancer chemotherapy was suboptimal and less commonly performed in community oncology clinics compared to teaching hospitals.
BACKGROUND:Cancerpatients receiving chemotherapy face an increased risk of reactivation of chronic hepatitis B virus infection. AIM: To determine the HBV screening rate in patients receiving cancer chemotherapy in various clinical settings. METHOD: We identified 11,959 adult cancerpatients (age ≥ 18 years) receiving parenteral chemotherapy between 2012 and 2015 within a major US hospital network, including a large university hospital, community teaching hospitals, and community oncology clinics. RESULT: Two thousand and forty-five patients (17.1%) were screened for either HBV surface antigen (HBsAg) or HBV core antibody (HBcAb) before chemotherapy, and 1850 patients (15.5%) had both HBsAg and HBcAb tested before chemotherapy. 8.4% were exposed to HBV, and 0.9% had chronic HBV infection (both HBsAg/HBcAb positive). Patients with hematologic tumor were more often screened than with solid tumor (55.6 vs. 8.3%, p < 0.001). Patients receiving chemotherapy with higher HBV reactivation risk had higher yet suboptimal HBV screening rate (41.1% B-depleting agents, 21.5% anthracycline, 14.9% steroid, 64.7% anti-TNF alpha and 18.6% other chemotherapy, p < 0.001). Patients with age ≥ 50 years (old 16.2% vs. young 23.9%, p < 0.001) and Asian ethnicity (Asian 13.6 vs. Caucasian 16.6%, p < 0.001) were screened less for HBV despite higher prevalence of HBV exposure (old 9.3% vs. young 4.3%, p < 0.001 and Asian 27.8% vs. Caucasian 6.4%, p < 0.001). Patients receiving chemotherapy in community oncology clinics were less screened versus community teaching hospitals or university hospital (12.7 vs. 19.1 vs. 19.7%, p < 0.001), despite similar prevalence of HBV infection. On multivariate analysis, receiving chemotherapy at a community oncology clinic [odds ratio (OR) 0.57, 95% confidence interval (CI) 0.45-0.72, p < 0.001] was independently associated with less HBV screening compared to receiving chemotherapy at a university or community teaching hospital. CONCLUSION: HBV screening among patients undergoing cancer chemotherapy was suboptimal and less commonly performed in community oncology clinics compared to teaching hospitals.
Entities:
Keywords:
Cancer chemotherapy; HBV prophylaxis; HBV reactivation; Hepatitis B; Rituximab
Authors: K Rajender Reddy; Kimberly L Beavers; Sarah P Hammond; Joseph K Lim; Yngve T Falck-Ytter Journal: Gastroenterology Date: 2014-10-31 Impact factor: 22.682
Authors: Kevin Junus; Maria Aguilar; Priya Patel; David Irwin; Stephen Yee; Benny Liu; Taft Bhuket; Robert J Wong Journal: Cancer Date: 2016-10-03 Impact factor: 6.860
Authors: Henry Roberts; Deanna Kruszon-Moran; Kathleen N Ly; Elizabeth Hughes; Kashif Iqbal; Ruth B Jiles; Scott D Holmberg Journal: Hepatology Date: 2015-10-27 Impact factor: 17.425
Authors: Rohit Loomba; Ayana Rowley; Robert Wesley; T Jake Liang; Jay H Hoofnagle; Frank Pucino; Gyorgy Csako Journal: Ann Intern Med Date: 2008-04-01 Impact factor: 25.391
Authors: Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Jessica P Hwang; Mark R Somerfield; Devena E Alston-Johnson; Donna R Cryer; Jordan J Feld; Barnett S Kramer; Anita L Sabichi; Sandra L Wong; Andrew S Artz Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544